Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DendroAnalgesic (home setting) is a nanoparticle-based opioid analgesic being developed by DendroPharm for the treatment of chronic severe pain. Utilizing the company's proprietary NanoOpiat technology, the drug consists of an opioid agonist encapsulated within a dendritic nanomaterial. This formulation is designed to target peripheral opioid receptors specifically, preventing the drug from crossing the blood-brain barrier. By restricting activity to the peripheral nervous system, DendroAnalgesic aims to provide potent pain relief without the central nervous system side effects typically associated with opioids, such as respiratory depression, sedation, addiction, and constipation. The candidate is specifically intended for use in a home setting and is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DendroAnalgesic (home setting).